• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿弥漫内生型桥脑胶质瘤的超长生存期:病例报告及文献复习。

Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.

机构信息

Faculty of Medicine, Université Laval.

Division of Radiation Oncology.

出版信息

J Pediatr Hematol Oncol. 2024 May 1;46(4):211-215. doi: 10.1097/MPH.0000000000002853. Epub 2024 Apr 4.

DOI:10.1097/MPH.0000000000002853
PMID:38573000
Abstract

Diffuse intrinsic pontine gliomas are lethal tumors with a prognosis generally less than 1 year. Few cases of survivors of 5 years or more have been reported. This case report highlights the journey of a 9.5-year survivor who underwent 3 rounds of focal radiotherapy; she experienced 6 years of progression-free survival following the first round but ultimately succumbed to her disease. An autopsy revealed a favorable IDH1 mutation and the absence of H3K27M. This case reiterates the importance of extensive molecular analyses in diffuse intrinsic pontine gliomas and explores the potential benefit of re-irradiation in patients with positive responses and long periods of remission.

摘要

弥漫性内生脑桥胶质瘤是致命的肿瘤,一般预后不到 1 年。报告的 5 年以上幸存者病例很少。本病例报告强调了一名 9.5 年幸存者的历程,她接受了 3 轮局部放疗;在第一轮治疗后,她经历了 6 年的无进展生存期,但最终还是死于疾病。尸检显示 IDH1 突变良好,H3K27M 缺失。本病例再次强调了在弥漫性内生脑桥胶质瘤中进行广泛分子分析的重要性,并探讨了对有阳性反应和长时间缓解的患者进行再放疗的潜在益处。

相似文献

1
Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.小儿弥漫内生型桥脑胶质瘤的超长生存期:病例报告及文献复习。
J Pediatr Hematol Oncol. 2024 May 1;46(4):211-215. doi: 10.1097/MPH.0000000000002853. Epub 2024 Apr 4.
2
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.溶瘤腺病毒Ad-TD-nsIL12治疗原发性或进展性儿童异柠檬酸脱氢酶野生型弥漫性脑桥胶质瘤的两项I期临床试验结果
Nat Commun. 2025 Jul 28;16(1):6934. doi: 10.1038/s41467-025-62260-5.
3
Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.开发弥漫性内生脑桥胶质瘤 H3K27M 突变体选择性放射增敏策略。
Neoplasia. 2023 Mar;37:100881. doi: 10.1016/j.neo.2023.100881. Epub 2023 Jan 30.
4
Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.成人 IDH 突变型脑桥胶质瘤的临床转归、影像学表现和遗传学特征。
Acta Neurochir (Wien). 2024 Jun 12;166(1):263. doi: 10.1007/s00701-024-06154-3.
5
A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection-Enhanced Delivery in Children With DIPG.一项关于盐酸尼莫司汀经对流增强递送用于弥漫性内生型脑桥胶质瘤儿童患者的多中心II期试验。
Cancer Sci. 2025 Jun;116(6):1679-1690. doi: 10.1111/cas.70054. Epub 2025 Mar 27.
6
Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature.弥漫性脑桥内胶质瘤治疗中的放射治疗及后续再放射治疗结果,以及再放射治疗文献的系统综述。
Pract Radiat Oncol. 2017 Mar-Apr;7(2):86-92. doi: 10.1016/j.prro.2016.11.005. Epub 2016 Nov 23.
7
Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC).桥脑胶质瘤:一项基于人群的10年研究:来自加拿大儿科脑肿瘤联盟(CPBTC)的报告
J Neurooncol. 2020 Aug;149(1):45-54. doi: 10.1007/s11060-020-03568-8. Epub 2020 Jul 7.
8
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.用于 H3K27M 突变型弥漫性中线脑胶质瘤的 GD2-CAR T 细胞疗法。
Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7.
9
Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.成人弥漫性内在脑桥胶质瘤:96 例患者的临床、放射学、病理学、分子特征和治疗。
J Neurosurg. 2022 Apr 8;137(6):1628-1638. doi: 10.3171/2022.2.JNS211920. Print 2022 Dec 1.
10
Indolent course of brainstem tumors with K27M-H3.3 mutation.具有 K27M-H3.3 突变的脑干肿瘤惰性病程。
Pediatr Blood Cancer. 2020 Mar;67(3):e28102. doi: 10.1002/pbc.28102. Epub 2019 Dec 2.

引用本文的文献

1
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.EphA3 靶向嵌合抗原受体 T 细胞在神经胶质瘤中有效,并产生治愈性记忆 T 细胞反应。
J Immunother Cancer. 2024 Aug 7;12(8):e009486. doi: 10.1136/jitc-2024-009486.